NCT03975647
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Tyrosine-Kinase Inhibitor, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Prior treatment with tucatinib, TDM1, lapatinib, neratinib, afatinib, trastuzumab deruxtecan (DS-8201a), or any other investigational anti-HER2, anti-EGFR, or HER2 TKI agent; Patients with leptomeningeal disease or untreated unstable symptomatic brain metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT03975647